Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Pancreatic Ductal Adenocarcinoma: early-phase trial registry
3 of 5 indexed Advanced Pancreatic Ductal Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Advanced Pancreatic Ductal Adenocarcinoma: 5 US clinical trials tracked, 3 recruiting.
Advanced Pancreatic Ductal Adenocarcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Bruno Bockorny, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-pancreatic-ductal-adenocarcinoma
OPEN 3 | RECR 60% | LATE 0 | EARLY 4 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Advanced Pancreatic Ductal Adenocarcinoma lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Pancreatic Ductal Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Pancreatic Ductal Adenocarcinoma is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Pancreatic Ductal Adenocarcinoma research.
Bruno Bockorny accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Pancreatic Ductal Adenocarcinoma enrolment sits around 110 participants.
Median target enrolment is 110 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.
-
Advanced Pancreatic Ductal Adenocarcinoma research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BeiGene
NCT06585488
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
SystImmune
NCT07021066
Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer
City of Hope Medical Center
NCT04887805
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT02921022
AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC
Bruno Bockorny
NCT05632328
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Pancreatic Ductal Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Pancreatic Ductal Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Pancreatic Ductal Adenocarcinoma page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Advanced Pancreatic Ductal Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bruno Bockorny sponsors the most Advanced Pancreatic Ductal Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Bruno Bockorny's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Pancreatic Ductal Adenocarcinoma condition card totals 5 registered trials; most-linked intervention Nab-paclitaxel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.